Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Endometrial Cancer
Clinical trial register · China

Endometrial Cancer Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19312 matching records held by the registry are in this view. Synced 30 Oct 2026, 03:17 UTC
19312
Studies in scope
all four open statuses
11893
Recruiting now
open to new participants
2029
Lead sponsors
across recruiting studies
Top sites
Beijing 23 Guangzhou 15 Chongqing 9 Hefei 7 Fuzhou 7
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking University People's Hospital6 AstraZeneca5 Fudan University3 Sun Yat-sen University3 Merck Sharp & Dohme LLC2
Site location
Beijing23 Guangzhou15 Chongqing9 Hefei7 Fuzhou7
All 35 locations
Target enrolment
to

Endometrial Cancer trials in China

47 of 19312 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Peking University People's Hospital
Not applicable
160
Beijing
2027-01-01
Recruiting
Stellate Ganglion Block and Dexmedetomidine for Postoperative Sleep in Women Undergoing Laparoscopic Gynecologic Surgery
NCT07860203Uterine Fibroids (Leiomyoma), Adenomyosis of Uterus, Endometriosis, Endometrial Cancer
Catherin Zhang
Not applicable
100
Huai'an
2026-10
Not yet open
TR115 in ARID1A-Mutated Advanced Solid Tumors
NCT07793318Ovarian Clear Cell Carcinoma, Endometrial Cancer, Stomach Cancer Recurrent, Urinary Bladder Cancer
DrugTR115
Tarapeutics Science Inc.
Phase 2
50
Shanghai
2026-09-20
Active, closed
The Second Hospital of Anhui Medical University
Not applicable
90
Hefei
2026-09-15
Recruiting
Liquid Biopsy-Based Early Screening for Endometrial Cancer in Regional Chinese Populations
NCT07892755Endometrial Cancer, Atypical Endometrial Hyperplasia
Guizhou Provincial People's Hospital
Observational
512
Guiyang
2026-08-10
Not yet open
Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia
NCT07714070Endometrial Neoplasms, Endometrial Cancer, Atypical Endometrial Hyperplasia, Progestin Resistance
DrugsOrlistat·Progestin
Peking University People's Hospital
Phase 2
48
Beijing
2026-07
Active, closed
Guizhou Provincial People's Hospital
Observational
52
Guiyang
2026-06-27
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
40
Guangzhou
2026-06-26
Recruiting
Intrauterine Injection of Type III Collage in FST of EC/AEH
NCT07377734Atypical Endometrial Hyperplasia, Endometrial Cancer
DrugProgestin
Wang Jianliu
Phase 2
30
Beijing
2026-01-30
Recruiting
Fudan University
Phase 2/3
260
Shanghai
2026-01-25
Active, closed
Cervical Cytology DNA Methylation for Endometrial Cancer Screening
NCT07874529Endometrial Cancer, DNA Methylation, Cytology, Cancer Screening
Lei Li
Observational
30,000
Beijing
2025-12-12
Recruiting
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
NCT07371663Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer), Gastric (Stomach) Cancer, Endometrial Cancer
Beijing Tide Pharmaceutical Co., Ltd
Phase 1/2
266
Beijing, Zhengzhou, Hangzhou
2025-12-03
Not yet open
Sun Yat-sen University
Phase 2
128
Guangzhou
2025-10-15
Recruiting
Daiichi Sankyo
Phase 3
710
Beijing, Changchun, Chengdu, Hangzhou, Jinan, Linyi, Nanchang, Nanning
2025-09-30
Recruiting
MH-ART vs CF-IMRT in Postoperative Cervical/Endometrial Cancer
NCT07584161Cervical Cancer, Endometrial Cancer
Xiaorong Hou
Not applicable
228
Beijing
2025-09-25
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
96
Shanghai
2025-08-21
Recruiting
AstraZeneca
Phase 3
800
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2025-08-01
Not yet open
Peking University People's Hospital
Phase 2
140
Beijing
2025-07-15
Recruiting
Cohort Study of Intrauterine Diseases
NCT07048327Endometrial Cancer, Endometrial Hyperplasia, Endometrial Polyps
Wenwen Wang
Observational
2,000
Wuhan
2025-07
Recruiting
Clinical Research on Moderately Hypofractionated Adaptive Postoperative Radiotherapy for High-Risk Endometrial Cancer
NCT07116213Endometrial Cancer, Hypofractionated Dose, Radiotherapy, Adjuvant, Side Effects
Xiaorong Hou
Not applicable
20
Beijing
2025-06-30
Recruiting
QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer
NCT06917092Endometrial Adenocarcinoma, Endometrial Cancer
DrugGemox
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2025-06-16
Recruiting
BioNTech SE
Phase 3
480
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shantou
2025-06-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,123
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang
2025-05-22
Recruiting
Fudan University
Phase 2
10
Shanghai
2025-04-21
Not yet open
Application-Assisted Weight Management in Endometrial Cancer Fertility Preservation
NCT06901778Endometrial Cancer, Mobile Applications, Weight Management
Peking University People's Hospital
Not applicable
106
Beijing
2025-03-31
Recruiting
AstraZeneca
Phase 3
600
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou
2025-03-27
Recruiting
Shanghai Best-Link Bioscience, LLC
Phase 1
9
Changchun, Jinan
2025-03-10
Not yet open
Fudan University
Phase 2
30
Shanghai
2024-11-30
Recruiting
Qilu Hospital of Shandong University
Not applicable
42
Jinan
2024-10-30
Recruiting
PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer
NCT06549855Endometrial Cancer, Endometrioid Carcinoma, Mismatch Repair Deficiency
DrugSintilimab
Peking University People's Hospital
Not applicable
10
Beijing
2024-09-02
Active, closed
Gilead Sciences
Phase 3
640
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangxi Zhuang Autonomous Region, Guangzhou, Hangzhou
2024-08-28
Recruiting
A Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors
NCT06531486Solid Tumor, Ovarian Cancer, Breast Cancer, Endometrial Cancer
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1
96
Beijing
2024-08-15
Not yet open
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
420
Hefei, Fuzhou, Lanzhou, Guangzhou, Huizhou, Jiangmen, Meizhou, Guigang
2024-07
Recruiting
The Safety, Tolerability, and Efficacy of KD01 in Gynecologic Malignancies
NCT06552598Cervical Cancer, Gynecologic Malignancies, Endometrial Cancer
DrugKD01
Tongji Hospital
Phase 1
97
Wuhan
2024-04-01
Recruiting
Peking Union Medical College Hospital
Not applicable
30
Beijing
2024-03-01
Not yet open
Myeloprotection With Trilaciclib in Pan-cancer Population
NCT06297811Non-Small Cell Lung Cancer, Breast Cancer, Endometrial Cancer, Cervical Cancer
DrugsTrilaciclib·Paclitaxel·Carboplatin
Sun Yat-sen University
Phase 2
132
Guangzhou
2024-03-01
Recruiting
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
NCT06014190Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
DrugHS-20089
Hansoh BioMedical R&D Company
Phase 2
460
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Haikou, Shijiazhuang
2023-12-18
Active, closed
Merck Sharp & Dohme LLC
Phase 3
710
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang, Nanning
2023-12-06
Recruiting
A Cohort Study of Uterine Malignancies
NCT05635123Cervical Cancer, Endometrial Cancer
Women's Hospital School Of Medicine Zhejiang University
Observational
6,200
Hangzhou
2023-09-15
Recruiting
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma
DrugsPalacaparib·Torvutatug samrotecan·Saruparib·Paraplatin
AstraZeneca
Phase 1/2
622
Chengdu, Chongqing, Guangzhou, Jinan, Xi'an, Zhengzhou
2023-06-05
Active, closed
Sun Yat-sen University
Phase 2
32
Guangzhou
2023-05-08
Recruiting
AstraZeneca
Phase 2
454
Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Shanghai, Shenyang, Wuhan
2022-09-06
Recruiting
AstraZeneca
Phase 1/2
460
Beijing, Changsha, Chongqing, Guangzhou, Kunming, Shandong
2021-10-18
Not yet open
Adjuvant Radiotherapy in Patients With Early Endometrial Cancer
NCT04956601Endometrial Cancer, Pathology, Radiotherapy
Peking University Third Hospital
Not applicable
480
Beijing
2021-07
Recruiting
Peking University People's Hospital
Not applicable
654
Beijing
2020-05-12
Active, closed
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
NCT04188548Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
DrugsImlunestrant·Alpelisib·Everolimus·Abemaciclib
Eli Lilly and Company
Phase 1
379
2019-12-10
Recruiting
Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC
NCT03463252Endometrial Cancer, Atypical Endometrial Hyperplasia
DrugsGnRH-a·Progesterone
West China Second University Hospital
Phase 2/3
224
Chengdu
2018-04-01
Rows per page Showing 1–47 of 47
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 October 2026. https://priyalifescience.com/clinical-trials-china/condition/endometrial-cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,312 studies in total at the last sync on 30 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 47 of those studies listing the condition Endometrial Cancer.

How many Endometrial Cancer trials are recruiting in China?

30 of the 47 studies on this page are recruiting new participants as of the 30 Oct 2026, 03:17 UTC sync. A further 10 have not yet opened recruitment, 7 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Endometrial Cancer), 47 studies
PhaseStudiesRecruitingShare
Phase 213627.7%
Not applicable12825.5%
Phase 38517%
Observational5310.6%
Phase 1438.5%
Phase 1/2336.4%
Phase 2/3224.3%

Most active sponsors

Lead sponsors with the most studies (Endometrial Cancer)
Lead sponsorStudiesRecruiting
Peking University People's Hospital62
AstraZeneca55
Fudan University32
Sun Yat-sen University30
Guizhou Provincial People's Hospital21
Merck Sharp & Dohme LLC21
Xiaorong Hou22
Beijing Tide Pharmaceutical Co., Ltd11
BioNTech SE11
Catherin Zhang11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.